Pushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel.1 This results in optimal vessel recovery and potentially shortened DAPT time.2Mastering rapid and healthy coronary vascular repair.
Terumo's sponsorship is subject to all necessary regulatory approvals.
No drug polymer coating on parts of the stent that experience the most physical stress.5
Gradient coating ensures polymer integrity reducing risk of delamination, even when overexpanded3
Test method: Expand a cell with a balloon at nominal pressureCell area: 14.5 mm²
Recommended DES in ESC/EACTS 2014 guidelines.6
1 month DAPT. CE Mark approved for patients in need.2
1 Data on file at Terumo Corporation (Doc nr. BioRes02-T).2 Ultimaster IFU. 1 month DAPT CE Mark approved for patients in need. Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month.3 Comparing to DES with uniform coating. Saito N. et al. Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. Medical Devices: Evidence and Research 2016:9.4 Virmani R. CvPath Rabbit Iliac artery. Barbato E. Presented at EuroPCR 2013.5 Data on file at Terumo Corporation (Doc nr. Grad01-T).6 Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Inter v. 2015 Aug 13. doi: 10.1002/ccd.26150.7 Windecker S et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619.